|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||September 01, 2012|
|Effective date (End):||August 31, 2013|
|Field of knowledge:||Health Sciences - Medicine - Maternal and Child Health|
|Principal Investigator:||Carlos Alberto Scrideli|
|Grantee:||Daniella Cembranelli Viana da Silva|
|Home Institution:||Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil|
The astrocytic tumors (gliomas) are the most frequent primary brain tumors in adults and children and the glioblastoma is the most malignant one in CNS (central nervous system). According to the actual treatment protocols, the survival is around 9 months. Despite the great progress on understanding the biology of these tumors in last decades, it wasn't decoded to effective therapies. The genetic expression profile of these tumors show new molecular alterations and cellular signaling pathways involved in proliferation. This technology allow the identification of new specific therapeutic targets in attempt to improve survival. In studies of our group evaluating differences of genetic expression by microarray technology, was observed that the gene CBFA2T2 showed the greatest difference of expression between non-neoplastic white brain mass and specimens of glioblastoma (1.327 times). This gene interact with a great amount of genes related to cell cycle and cancer and it seems to become an important role at neuronal differentiation. They'll be analysed 40 samples of primary glioblastomas, 30 samples of pylocitic astrocitomas and 15 of healthy white brain mass (acquired by temporal lobectomy in epilepsy surgical therapies) by quantitative real-time PCR to CBFA2T2 expression using TaqMan probes. The aim of the study is to analyze the association between the levels of expression of CBFA2T2 and the clinic-biological and histopatologycal properties of these tumors as histological subtype, age, gender and survival.